Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd (TLSA) is a clinical-stage biotechnology innovator developing intranasal immunotherapies for neurodegenerative and inflammatory diseases. This page provides centralized access to official corporate announcements, clinical trial updates, and strategic developments.
Investors and researchers will find timely updates on TLSA's novel drug delivery platform, including progress with intranasal foralumab and other candidates targeting multiple sclerosis, Alzheimer's, and autoimmune conditions. The repository includes press releases on FDA communications, partnership announcements, and peer-reviewed research findings.
Key content categories include clinical trial milestones, intellectual property updates, executive leadership changes, and financial performance reports. All materials are sourced directly from the company and verified financial news outlets to ensure accuracy.
Bookmark this page for streamlined tracking of TLSA's progress in advancing non-invasive immunotherapy solutions. Check regularly for updates on groundbreaking approaches to modulating immune responses through nasal administration.
Tiziana Life Sciences (NASDAQ: TLSA) announced a TV feature highlighting their first patient treated with intranasal foralumab for moderate Alzheimer's disease through their expanded access program. The segment showcased Joe and his wife Karen sharing their experience with the treatment.
Foralumab is a fully human anti-CD3 monoclonal antibody administered intranasally, targeting immune system dysregulation in Alzheimer's disease. The treatment aims to reduce inflammation by modulating microglial activation, a critical component in neurodegenerative diseases. The therapy works by inducing Tregs that travel to the brain to modulate neuroinflammation, an approach that has shown efficacy in animal models and MS patients.
This expanded access program allows patients without clinical trial access to receive the treatment through compassionate use. The therapy represents a potential complementary approach to existing anti-amyloid treatments, addressing neuroinflammation in Alzheimer's disease.
Tiziana Life Sciences (NASDAQ: TLSA) announced positive results from studies using nasal anti-CD3 monoclonal antibody in treating traumatic spinal cord injury (SCI). The preclinical model demonstrated notable improvements in motor functions after treatment with nasal anti-CD3.
The research showed the treatment's effectiveness in modulating microglial inflammation associated with SCI and dampening microglial activation. This advancement is significant given that approximately 300,000 individuals live with SCI in the U.S., with over 17,000 new cases annually.
The company is expanding its nasal foralumab technology from applications in neurologic diseases like secondary progressive multiple sclerosis to include spinal cord injury treatment, addressing a significant unmet medical need.
Tiziana Life Sciences (Nasdaq: TLSA) has announced its decision not to engage in capital raising activities in the immediate future. This announcement follows the company's recent discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with nasal foralumab, their lead development candidate. Foralumab is a fully human, anti-CD3 monoclonal antibody being developed as an intranasal immunomodulation therapy. The company's management emphasized their commitment to delivering shareholder value and advancing their drug candidates through clinical trials and regulatory processes.
Tiziana Life Sciences (NASDAQ: TLSA) has announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with nasal foralumab. The findings were observed in their ongoing ISPPEA expanded access program through single-cell RNA sequencing of blood samples taken before, three, and six months after drug administration.
The study identified key gene expression changes in several immune cell types, including FoxP3 T regulatory cells, CD4+ and CD8+ central memory T cells, CD14+ and CD14- monocytes, and Naïve B cells. These changes were associated with a reduction in microglial brain inflammation, as measured by advanced PET scans.
The company's intranasal foralumab, a fully human anti-CD3 monoclonal antibody, is currently in Phase 2 trials. The biomarker discoveries are expected to help monitor treatment efficacy and patient response in future trials.
Tiziana Life Sciences (Nasdaq: TLSA) has announced promising findings regarding its nasal anti-CD3 monoclonal antibody, which mitigates side effects associated with the discontinuation of GLP-1 agonists. These drugs, used for treating metabolic disorders, often lead to side effects like muscle and bone loss, causing patients to stop treatment and lose the benefits of tissue homeostasis. Tiziana's therapy not only enhances the positive effects of semaglutide, a GLP-1 agonist but also sustains these benefits even after discontinuation.
Dr. Howard Weiner highlighted that nasal anti-CD3 provides a novel and non-toxic method for maintaining tissue homeostasis and improving patient outcomes. Researcher Selma Boulenouar PhD, noted that the therapy sustains tissue homeostasis and mitigates inflammation in key organs, including adipose tissue, liver, kidneys, and brain, even on a high-fat diet. The therapy's efficacy is attributed to its ability to induce regulatory T cells, which reduce tissue inflammation.
CEO Ivor Elrifi emphasized that these findings represent a significant advancement in treating metabolic and age-related diseases by maximizing the therapeutic benefits of GLP-1 drugs while minimizing associated risks.
Tiziana Life Sciences (NASDAQ: TLSA) announced the publication of a review article in Nature Reviews Neurology highlighting the therapeutic potential of their lead candidate, intranasal foralumab, in treating various neurodegenerative diseases. The article emphasizes how the immune system plays a important role in conditions like Multiple Sclerosis (MS), Alzheimer's, ALS, and Parkinson's disease.
The review discusses how foralumab targets components of the peripheral immune system and dampens microglia activation in MS. Dr. Howard Weiner, Chairman of Tiziana's Scientific Advisory Board, highlighted that intranasal foralumab represents a promising treatment approach, noting its ability to act without apparent side effects and ease of administration.
The article explores how microglia, monocytes, and T cells contribute to disease pathogenesis and their potential as shared therapeutic targets across multiple neurological conditions.
Tiziana Life Sciences (NASDAQ: TLSA) has achieved a significant milestone by dosing the first patient with moderate Alzheimer's disease using intranasal foralumab at Brigham and Women's Hospital in Boston. The treatment, a fully human anti-CD3 monoclonal antibody, aims to reduce brain inflammation through a unique mechanism that stimulates T regulatory cells to cross the blood-brain barrier and reduce neuroinflammation of glial cells.
This approach differs from traditional beta amyloid removal or tau protein reduction methods. The study is part of a broader development program that received a $4 Million NIH grant in September 2024. Dr. Howard Weiner, the Principal Investigator, notes that there are currently no approved drugs for moderate Alzheimer's disease, highlighting the potential significance of this novel treatment approach.
Tiziana Life Sciences (NASDAQ: TLSA) has expanded its Phase 2 clinical trial for intranasal foralumab in non-active secondary progressive multiple sclerosis (SPMS) to include prestigious medical centers across the Northeast United States. The trial now encompasses Yale University, Johns Hopkins University, Cornell University, University at Buffalo, University of Massachusetts, and Thomas Jefferson University.
The strategic selection of Northeast locations enables all trial participants to receive PET scans at a single imaging site at Invicro in New Haven, Connecticut, minimizing scan variability. This expansion is particularly significant as non-active SPMS currently has no FDA-approved therapeutic options. The company's intranasal foralumab offers a unique approach by targeting inflammation and modulating the immune system without systemic immune suppression.
Tiziana Life Sciences (NASDAQ: TLSA) has received a grant from the ALS Association through the Hoffman ALS Clinical Trial Awards Program to fund a 20-patient clinical trial of intranasal foralumab, their lead development candidate. The trial will evaluate safety and early-stage disease improvement parameters in ALS patients. Foralumab, a fully human anti-CD3 monoclonal antibody, has shown promise in treating Multiple Sclerosis, with positive results in 10 patients under an Expanded Access Program. The FDA has approved enrollment of 20 additional patients in this program.
Tiziana Life Sciences (Nasdaq: TLSA) announced its participation in BIO-Europe 2024, scheduled for November 4-6 in Stockholm, Sweden. The company will showcase its recent clinical advancements, particularly focusing on its combination study data involving Ozempic, a GLP-1 agonist, and its lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody.
CEO Ivor Elrifi highlighted the conference as an opportunity to present their latest clinical findings and engage with potential partners. The company aims to leverage this platform to discuss strategic partnerships and showcase their therapeutic pipeline development, following a successful fundraising round that supports their ongoing Phase 2 studies.
FAQ
What is the current stock price of Tiziana Life Sciences Com (TLSA)?
What is the market cap of Tiziana Life Sciences Com (TLSA)?
